Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Depreciation & Amortization (CF): 2014-2024

Historic Depreciation & Amortization (CF) for Cidara Therapeutics (CDTX) over the last 11 years, with Dec 2024 value amounting to $200,000.

  • Cidara Therapeutics' Depreciation & Amortization (CF) fell 31.71% to $28,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $177,000, marking a year-over-year increase of 20.41%. This contributed to the annual value of $200,000 for FY2024, which is 78.57% up from last year.
  • As of FY2024, Cidara Therapeutics' Depreciation & Amortization (CF) stood at $200,000, which was up 78.57% from $112,000 recorded in FY2023.
  • Cidara Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $300,000 during FY2020, with a 5-year trough of $112,000 in FY2023.
  • In the last 3 years, Cidara Therapeutics' Depreciation & Amortization (CF) had a median value of $143,000 in 2022 and averaged $151,667.
  • Per our database at Business Quant, Cidara Therapeutics' Depreciation & Amortization (CF) crashed by 33.33% in 2021 and then soared by 78.57% in 2024.
  • Cidara Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $300,000 in 2020, then tumbled by 33.33% to $200,000 in 2021, then fell by 28.50% to $143,000 in 2022, then fell by 21.68% to $112,000 in 2023, then soared by 78.57% to $200,000 in 2024.